Acknowledgements
Nelson, P., A., Cancer
CANCER, NELSON, MAY, ONCOLOGY, FARBER, BROWN
This study was funded by Repare Therapeutics, Inc. The authors would like to thank the patients, their families and all investigators involved in the TRESR study. We also thank the Precision Oncology Decision Support Group at The University of Texas MD Anderson Cancer Center for providing genomic decision support through prospective annotation of all genomic alterations on NGS testing at study enrollment. We also thank the participating TRESR study sites for their work and contributions: B. Hoadley, C. Brown and S. Montez—The University of Texas MD Anderson Cancer Center; M. Liebers and A. Greenberg—Dana Farber Cancer Institute; I. Schafer—Sarah Cannon Research Institute/Tennessee Oncology; A. Kazarian—Memorial Sloan Kettering Cancer Center; P. Lee—Duke Cancer Institute; J. Hubbard—Massachusetts General Hospital; B. Travers and V. Nelson—Rhode Island Hospital/Lifespan; R. Wildman and A. Adile—Princess Margaret Cancer Center; T. Wood and P. Huddar—Christie NHS Foundation Trust; H. (Blair) Porteous—Newcastle Hospital NHS Foundation Trust; S. Mahmud and P. Rigby—Sarah Cannon Research Institute UK; and C. Sonander Westphal and E.-S. Sønderskov Darre—Righospitalet, Denmark. We thank NeoGenomics Laboratories, Tempus, Invitae Corporation and BioAgilytix for biomarker data collection. We thank the Repare clinical study team: A. Rode, S. Guerrera, L. Gjylameti, P. Nejad, S. May, S. Patel, B. Bazdar-Vinovrski, A. DeMaggio and ProPharma Group. We thank M. Zimmermann and D. Durocher for contributions during manuscript review and S. Harris for genomic profiling support. Critical review and editorial support were provided by A. A. Terbush and B. Fitzgerald of Onyx (London, UK), supported by Repare Therapeutics, Inc. This research was funded by Repare Therapeutics, Inc. All authors accept final responsibility for the content of the manuscript and for the decision to submit the manuscript for publication.